

Two isoleucyl tRNAs that decode 'synonymous' codons divergently regulate breast cancer progression

Lisa B. Earnest-Noble¹, Dennis Hsu¹, Hosseinali Asgharian²⁻³, Mandayam Nandan¹, Maria C. Passarelli¹, Hani Goodarzi^{2-4*}, Sohail F. Tavazoie^{1,*}

¹ Laboratory of Systems Cancer Biology,
The Rockefeller University,
1230 York Avenue,
New York, NY 10065, USA.

² Department of Biochemistry and Biophysics, ³Urology, and ⁴Helen Diller Family
Comprehensive Cancer Center, University of California, San Francisco, San
Francisco, CA 94158, USA

* To whom correspondence should be addressed. E-mail:
stavazoie@rockefeller.edu and hani.goodarzi@ucsf.edu

1 **The human genome contains 61 codons that encode for the 20 amino acids.**
2 **The synonymous codons of a given amino acid are decoded by a set of**
3 **transfer RNAs (tRNAs) called isoacceptors. We report the surprising**
4 **observation that two isoacceptor tRNAs that decode synonymous codons**
5 **are modulated in opposing directions during breast cancer progression.**
6 **Specifically, tRNA^{lle}_{UAU} is upregulated, whereas tRNA^{lle}_{GAU} is repressed as**
7 **breast cancer cells attained enhanced metastatic capacity. Functional**
8 **studies revealed that tRNA^{lle}_{UAU} promoted and tRNA^{lle}_{GAU} suppressed**
9 **metastatic colonization. The expression of these tRNAs mediated opposing**
10 **effects on codon-dependent translation of growth promoting genes.**
11 **Consistent with this, multiple mitotic gene sets in the human genome are**
12 **significantly enriched in the codon cognate to the growth-promoting**
13 **tRNA^{lle}_{UAU} and significantly depleted of the codon cognate to the growth-**
14 **suppressive tRNA^{lle}_{GAU}. Our findings uncover a specific isoacceptor tRNA**
15 **pair that act in opposition—divergently regulating genes that contribute to**
16 **growth and a disease phenotype. The degeneracy of the genetic code can**
17 **thus be biologically exploited by human cancer cells via tRNA isoacceptor**
18 **shifts that facilitate the transition towards a growth-promoting state.**

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Main

47

48 Because of the degeneracy of the genetic code, multiple transfer RNAs (tRNAs)
49 bearing distinct anticodons can accept the same amino acid for translational
50 incorporation into the growing polypeptide chain during translation^{1,2}. Such tRNA
51 isoacceptors recognize what are called 'synonymous codons'. Transfer RNAs
52 have long been considered static adaptor molecules that play critical roles in
53 converting the genetic code to an amino acid code. This notion has been revisited
54 in recent years with observations of altered expression of tRNAs in the context of
55 disease³⁻⁵, as well as demonstrated roles for certain over-expressed tRNAs (by
56 genomic amplifications) as promoters of tumourigenic phenotypes^{3,4,6}. Analogous
57 to these observations, aminoacyl tRNA synthetases (aaRS), responsible for
58 charging tRNAs with cognate amino acids, have been shown to play non-canonical
59 roles⁷ and recent work has demonstrated significant cancer progression roles for
60 specific charging enzymes^{8,9}. These studies have raised a number of questions,
61 including whether transcriptional deregulation in the absence of tRNA genomic
62 copy number alterations can modulate tRNA levels and cancer progression as well
63 as whether there exist metastasis suppressor tRNAs in human cancer.

64 Isoleucyl tRNA isoacceptors are divergently modulated in breast cancer

65

66 To identify tRNAs that may become transcriptionally modulated during cancer
67 progression, we performed chromatin immunoprecipitation sequencing (ChIP-seq)
68 in poorly and highly metastatic human breast cancer cells¹⁰ using an antibody
69 targeting the DNA binding subunit of Polymerase III, POLR3A. Enrichment of tRNA
70 loci was confirmed by successful co-immunoprecipitation of Pol III genomic target
71 loci through quantitative real-time PCR (qPCR) (Supplementary Fig. 1a), as well
72 as significant enrichment of ChIP-seq reads for tRNA Box A and Box B gene
73 regulatory sequences (Supplementary Fig. 1b). We observed that an isoleucyl-
74 tRNA (TAT) isoacceptor locus that encodes tRNA^{Ile}_{UAU} was significantly more
75 bound by Pol III in highly metastatic MDA-LM2 cells relative to the parental poorly-
76 metastatic MDA-MB-231 cells from which it was derived (Fig. 1a). To confirm these
77 findings and to establish that mature tRNA^{Ile}_{UAU} levels are upregulated in
78 metastatic cells, we performed targeted tRNA profiling by tRNA Capture-seq⁴.
79 Targeted tRNA quantification in the MDA-MB-231 poorly/highly metastatic pair as
80 well as an independent poorly/highly metastatic isogenic human breast cancer line
81 pair (HCC1806-Par and HCC1806-LM2C, validated in Supplementary Fig. 1c)
82 confirmed that mature tRNA^{Ile}_{UAU} is upregulated in highly metastatic breast cancer
83 cells relative to isogenic poorly metastatic cells (Fig. 1b). Northern blot analysis
84 confirmed the observations of tRNA^{Ile}_{UAU} over-expression in highly metastatic
85 breast cancer cells (Supplementary Fig. 1d). Genomic copy number analysis by
86 qPCR did not reveal increased genomic copy number of isoleucyl-tRNA (TAT) loci
87 in highly metastatic cells, consistent with transcriptional enhancement
88 (Supplementary Fig. 1e). In parallel to these observations, we made the surprising
89 observation that one of the other isoacceptors of isoleucine, tRNA^{Ile}_{GAU}, became
90 significantly repressed in the highly metastatic sublines relative to isogenic poorly
91 metastatic parental cells (Fig 1c). The high sequence similarity between tRNA^{Ile}_{GAU}

92 and another isoleucine isoacceptor tRNA^{Ile}_{AAU} precluded specific northern blot
93 quantification for tRNA^{Ile}_{GAU} as an independent tRNA quantification method. We
94 thus employed pre-tRNA quantification as an orthogonal approach for assessing
95 the levels of all three isoleucyl tRNAs. Pre-tRNA qRT-PCR also revealed
96 upregulation of tRNA^{Ile}_{UAU} expression by the multiple genomic loci that encode it
97 and conversely, repression of tRNA^{Ile}_{GAU} loci genes in both pairs of highly
98 metastatic breast cancer cells relative to their isogenic poorly metastatic parental
99 cell populations (Fig 1d-e). We did not observe such global modulations of the third
100 isoleucyl isoacceptor pre-tRNA^{Ile}_{AAU} across the loci surveyed (Supplementary Fig.
101 1f). In support of these findings, FISH staining of human tissue microarrays of
102 breast cancer patients with locked nucleic acids (LNAs) targeting tRNA^{Ile}_{UAU} and
103 tRNA^{Ile}_{GAU} revealed a significantly increased ratio of tRNA^{Ile}_{UAU}/tRNA^{Ile}_{GAU}
104 expression in stage III breast tumours, which exhibit higher rates of metastatic
105 relapse, relative to stage I or stage II tumours, which exhibit lower rates of
106 metastasis (Fig. 1f). These findings reveal that metastatic progression in breast
107 cancer selects for upregulation of one isoleucyl tRNA isoacceptor and repression
108 of another. This shift in tRNA isoleucyl isoacceptor levels suggests potentially
109 differential roles for these tRNAs in breast cancer progression.

110 **tRNA^{Ile}_{UAU} promotes and tRNA^{Ile}_{GAU} suppresses breast cancer metastasis**

111

112 To determine if the observed reciprocal tRNA isoleucyl isoacceptor modulations
113 play causal roles in cancer progression, we performed loss-of-function and gain-
114 of-function studies for these tRNA isoacceptors. We first sought to overexpress
115 tRNA^{Ile}_{UAU} in poorly metastatic cells to assess whether its upregulation was
116 sufficient to confer increased metastatic capacity (Supplementary Fig. 2a-b).
117 Stable over-expression of tRNA^{Ile}_{UAU} to pathophysiologically relevant levels (~50%
118 increase) in poorly metastatic MDA-MB-231 or HCC1806 human cell lines
119 significantly increased lung metastatic colonization in tail-vein colonization assays
120 as assessed by bioluminescence imaging and histological analyses (Fig. 2a-b).
121 For loss-of-function studies, we employed CRISPR-Cas9 using two independent
122 guides specific to tRNA^{Ile}_{UAU} genomic loci (Supplementary Fig. 2c). CRISPR-Cas9
123 mediated depletion of tRNA^{Ile}_{UAU} in highly metastatic MDA-LM2 breast cancer cells
124 to levels similar to poorly metastatic cells was sufficient to significantly impair
125 breast cancer metastatic colonization (Fig. 2c). These findings reveal tRNA^{Ile}_{UAU} to
126 be a promoter of metastatic progression in these human breast cancer cells.

127

128 We next determined if tRNA^{Ile}_{GAU}, which became repressed in metastatic cells,
129 plays a causal role in breast cancer progression. tRNA^{Ile}_{GAU} was stably
130 overexpressed in highly metastatic MDA-LM2 cells to levels similar to those
131 observed in poorly metastatic MDA-231 parental cells (~1.8-fold over-expression)
132 (Supplementary Fig. 2d). Increasing tRNA^{Ile}_{GAU} expression in highly metastatic
133 MDA-LM2 cells substantially reduced metastatic lung colonization capacity (Fig.
134 2d). Given the high sequence similarity between tRNA^{Ile}_{GAU} and tRNA^{Ile}_{AAU}, we
135 employed two orthogonal approaches for tRNA^{Ile}_{GAU} loss-of-function—CRISPRi
136 and shRNA mediated interference. Firstly, MDA-231 cells were stably transduced
137 with mutant Cas9-KRAB and a specific guide complementary to common

138 sequences in tRNA^{lle}_{GAU} genomic loci. Reduced tRNA^{lle}_{GAU} was confirmed by
139 targeted tRNA capture qPCR (Supplementary Fig. 2e). ShRNA-mediated
140 interference was also employed using a hairpin specific to tRNA^{lle}_{GAU}
141 (Supplementary Fig. 2f). Depletion of tRNA^{lle}_{GAU} using both approaches enhanced
142 lung metastatic colonization by poorly metastatic MDA-231 cells (Fig. 2e and 2f).
143 These findings implicate tRNA^{lle}_{GAU} as a metastasis suppressor tRNA and uncover
144 two surprising findings: the first being a gain-of-function organismal disease
145 phenotype upon depletion of a tRNA (tRNA^{lle}_{GAU}); the second being the
146 observation of a dichotomy between two tRNA isoacceptors in regulating a
147 common phenotype.

148 **TRNA^{lle} isoacceptors divergently regulate growth and growth gene** 149 **expression**

150
151 We next sought to identify the cancer progression cellular phenotype(s) regulated
152 by tRNA^{lle}_{UAU} and tRNA^{lle}_{GAU} by searching for gene sets that exhibit enrichments
153 or depletions of codons cognate to these tRNAs. We performed pathway
154 enrichment analyses using the iPAGE framework¹¹—assessing significant
155 genome-wide abundances for the codons cognate to tRNA^{lle}_{UAU} and tRNA^{lle}_{GAU} in
156 an unbiased manner. All coding transcripts in the human genome were ranked
157 and binned by AUA or AUC relative synonymous codon usage (RSCU). Pathways
158 that were significantly enriched ($p < 10^{-3}$) across discretized bins were identified
159 based on their mutual information content (Fig. 3a-b). Interestingly, transcripts
160 most significantly enriched in AUA codons (cognate to tRNA^{lle}_{UAU}) were enriched
161 in mitosis related gene sets such as metaphase, anaphase, and chromatid
162 separation, and homologous DNA pairing and strand exchange (Fig. 3a).
163 Conversely, AUC codons (cognate to tRNA^{lle}_{GAU}) were most significantly depleted
164 from these mitosis related gene sets (Fig. 3b). As an orthogonal and functional
165 approach for identifying the downstream consequences of modulation of these
166 tRNAs, we conducted ribosomal profiling of breast cancer cells in the context of
167 tRNA^{lle}_{UAU} overexpression and tRNA^{lle}_{GAU} depletion (by CRISPRi), mirroring the
168 divergent tRNA^{lle} modulations observed in highly metastatic cells relative to poorly
169 metastatic cells. Ribosomal protected fragments were sequenced, and conformed
170 to the expected size and periodicity reported by other groups¹² (Supplementary
171 Fig. 3a-b). Ribosomal occupancy of transcripts was then quantified as a measure
172 of translational efficiency (Supplementary Fig 3c). Genes enriched in GO terms
173 such as cell cycle and mitosis exhibited enhanced translational efficiency (Fig. 3c).
174 At the proteomic level, GO functional analysis of proteins in tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU}
175 modulated cells by label free mass spectrometric quantification also revealed
176 enrichment of gene sets including cell cycle, mitosis, as well as regulation of stress
177 response relative to control cells (Fig. 3d). Consistent with the growth related gene
178 sets identified using the described approaches, immunofluorescent staining of
179 metastatic nodules for the proliferation marker Ki67 revealed that MDA MB 231
180 breast cancer cells concomitantly over-expressing tRNA^{lle}_{UAU} and depleted of
181 tRNA^{lle}_{GAU} exhibited greater proliferation than control cells (Fig. 3e, Supplementary
182 Fig. 3d). To determine if these *in vivo* observations could be recapitulated *in vitro*,
183 growth assays were performed under normal tissue culture conditions and under

184 conditions of hypoxic and oxidative stress, since such stresses occur in the
185 metastatic microenvironment and can restrict growth¹³⁻¹⁸. Concomitant tRNA^{lle}_{UAU}
186 upregulation/tRNA^{lle}_{GAU} depletion enhanced the *in vitro* growth of MDA MB 231
187 breast cancer cells relative to control cells in the context of hypoxia (Fig. 3f) and
188 oxidative stress (Fig. 3g). Importantly, growth effects were more pronounced under
189 these stress conditions that are known to occur in the tumour microenvironment
190 than under normoxic basal *in vitro* conditions (Supplementary Fig. 3e). These
191 findings reveal that divergent modulation of these isoleucyl tRNA isoacceptors
192 promotes growth in these breast cancer cells *in vivo* and *in vitro*.

193 **A growth gene network regulated by tRNA^{lle} isoacceptors**

194
195 We next sought to identify examples of downstream effector genes that could
196 mediate cell growth effects downstream of tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU} modulation. We
197 hypothesized that there exist growth-promoting genes enriched in AUA codons
198 cognate to tRNA^{lle}_{UAU}. We identified the set of genes that exhibited enhanced
199 translational efficiency as well as enhanced mass-spectrometric protein
200 abundances upon concurrent tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU} modulation, and exhibited a
201 high relative synonymous codon usage score for tRNA^{lle}_{UAU}. The ten genes that
202 fulfilled these criteria were further restricted to those that exhibited enhanced
203 translational efficiencies and protein abundances in highly metastatic cells, which
204 endogenously modulate these tRNAs relative to the isogenic parental poorly
205 metastatic population (Fig. 3h)⁴. This yielded six genes as candidate downstream
206 growth-promoting effectors (Supplementary Fig. 3f). Functional testing revealed
207 that RNAi-mediated depletion of three of these genes (*SMNDC1*, *LSM6*, and
208 *PYCARD*) reduced proliferation (3i-k, Supplementary Fig. 3g, h). We next focused
209 on one gene, *SMNDC1*, for mutagenesis studies. To determine if isoleucyl tRNA
210 modulations can directly enhance translation of a growth-promoting gene in a
211 codon-dependent manner, we employed a reporter-based approach in which AUA
212 codons in *SMNDC1* were mutated to synonymous AUC codons. While the wildtype
213 *SMNDC1* protein became upregulated upon dual tRNA modulation, synonymous
214 codon mutant *SMNDC1* protein levels remained unchanged (Fig. 3l, m)—
215 consistent with codon-dependent tRNA^{lle}_{UAU}-driven enhancement of translation of
216 this growth-promoting gene. These findings reveal that divergent isoleucyl tRNA
217 modulation enhances translation of a set of growth-promoting genes with high
218 tRNA^{lle}_{UAU} relative synonymous codon usage scores.

219 220 **Divergent tRNA isoacceptor modulation impacts ribosomal function**

221
222 The opposing directionality of the metastasis phenotype observed upon
223 modulating these isoacceptor tRNAs suggests that they may elicit distinct
224 downstream codon-dependent translational effects at a global level. To test this,
225 we performed polysome profiling studies (Supplementary Fig. 4a). This revealed
226 that relative to control cells, concurrent tRNA^{lle}_{UAU} over-expression and tRNA^{lle}_{GAU}
227 depletion elicited a significant increase in polysome occupancy of transcripts
228 enriched in the AUA codon, which is cognate to the over-expressed tRNA^{lle}_{UAU} (z-
229 score 23.6; robustness 10/10; Fig. 4a) and a reduction in actively translating

230 transcripts enriched in the AUC codon, which is cognate to the depleted tRNA^{lle}_{GAU}
231 (z-score 44.8; robustness 10/10; Fig. 4b). Consistent with this, analysis of the
232 aforementioned ribosomal profiling data revealed that upon dual
233 tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU} modulation, there was also a significant enrichment of
234 ribosomal occupancy of AUA-containing transcripts and reduced occupancy of
235 AUC-containing transcripts (Supplementary Fig. 4b,c). Our findings as a whole
236 suggest a model whereby tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU} modulation enhances the
237 efficiency of AUA codon decoding by the ribosome. This would suggest that we
238 should observe reduced ribosomal dwell time over AUA codons upon dual tRNA
239 modulation. Moreover, we would expect to see increased binding of tRNA^{lle}_{UAU}
240 relative to tRNA^{lle}_{GAU} to the ribosome upon tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU} modulation. In
241 order to capture the dwell time of ribosome at every codon, we measured the
242 extent to which its occupancy in the ribosome profiling data deviates from its
243 predicted level based on loess regression¹⁹. We observed that
244 tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU} modulation significantly reduced ribosome dwell time over
245 AUA codons, consistent with productive translation, while over-expression of
246 tRNA^{lle}_{UAU} or depletion of tRNA^{lle}_{GAU} individually were insufficient to elicit significant
247 shifts in dwell time (Fig. 4c). To determine if tRNA modulations impact ribosome-
248 associated tRNA^{lle}_{UAU} and tRNA^{lle}_{GAU} abundances, we quantified the abundance
249 of these tRNAs from polysomal ribosomes as well as total cellular input. We
250 observed that tRNA^{lle}_{GAU} depletion reduced the ribosomal association of this tRNA,
251 while tRNA^{lle}_{UAU} over-expression enhanced its ribosome association (Fig. 4f).
252 Importantly, dual tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU} modulation caused the greatest increase in
253 relative tRNA^{lle}_{UAU} to tRNA^{lle}_{GAU} ribosomal association (Fig. 4g). The substantially
254 increased ribosomal association of tRNA^{lle}_{UAU} upon dual tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU}
255 modulation relative to tRNA^{lle}_{GAU} depletion supports the translational
256 consequences observed upon polysome profiling (Fig. 4d, e). These concordant
257 observations of global shifts in isoleucine codon enrichments and depletions in
258 polysome profiling and ribosomal profiling studies as well as dwell time and
259 biochemical analyses support direct codon-dependent effects on translation upon
260 divergent modulation of these tRNAs. Our findings as a whole support a model
261 whereby isoleucyl isoacceptor tRNA abundance shifts impact codon-dependent
262 translation of growth regulating genes at the ribosome, thereby promoting cancer
263 progression (Fig. 4h).

264

265 Discussion

266

267 Our observations reveal opposing roles for two isoleucyl tRNAs in regulation of
268 breast cancer metastatic colonization and cancer cell growth. Our findings as a
269 whole support a model whereby shifts in tRNA^{lle} isoacceptor abundance impact
270 codon-dependent translation of growth regulating genes at the ribosome, thereby
271 promoting cancer progression (Fig. 4h). The molecular and functional studies
272 implicating growth as a phenotype divergently impacted by modulation of these
273 tRNAs is supported by genome sequence analyses that reveal significant
274 enrichment or depletion of the codons cognate to these antagonistic tRNAs in
275 mitotic gene sets. Future studies are warranted to better elucidate the molecular

276 basis of such interferences and to search for additional examples of such
277 antagonistic isoacceptor tRNA pairs in health and disease.

278

279 **Methods**

280

281 **Cell Culture**

282 MDA-MB-231 and its highly metastatic derivative¹⁰ LM2 cells were cultured with
283 DMEM media supplemented with 10% FBS, sodium pyruvate, and L-glutamine.
284 HCC1806 Parental and derivate cell lines were cultured in 1x RPMI supplemented
285 with 10% FBS, sodium pyruvate, 1mM HEPES as specified by ATCC. All cell lines
286 were regularly tested for mycoplasma infection and were negative. Each cell line
287 was verified using STR testing, performed by the Integrated Genomics Operation
288 at MSKCC. Cells were retrovirally transduced with a luciferase reporter for
289 bioluminescence detection as previously described^{4,15,20}. Oxidative stress
290 analyses were conducted by addition of 200 uM hydrogen peroxide to cells.

291

292 **In Vivo Selection**

293 Several female Nod SCID Gamma (NSG) (Jackson # 005557) mice were injected
294 at 6 weeks of age intravenously via tail vein with 150,000 parental HCC1806 cells
295 and monitored by bioluminescence IVIS imaging (IVIS Lumina II) until photon flux
296 of lungs reached 10^7 or 10^8 (4-7 weeks). Subsequently, animals were
297 euthanized according to IACUC protocol and guidelines, and the lungs were
298 extracted under sterile conditions. The lungs were then placed on a sterile 6cm
299 tissue culture dish and minced with razor blades. Lung tissue extracts were re-
300 suspended in 20 mL RPMI Media supplemented with FBS, sodium pyruvate and
301 HEPES with 15 mg/mL Collagenase IV (Worthington). Cells were incubated at
302 37°C for 30 minutes on a shaker to allow for digestion. Tissue extracts were then
303 spun down at 1000 RPM for 5 minutes at 4°C and resuspended in RPMI media
304 without Collagenase IV. Cells were filtered with a 100 um filter (Corning) and spun
305 down again. Cells were then treated with 5 mL ACK Lysis Buffer and left at room
306 temperature for 5 minutes. Cells were spun again and resuspended in 1 mL
307 Optiprep solution 1 (2:1, Optiprep:Media). A gradient was constructed with an
308 additional 4 mL Solution 1, overlain by 3 mL Optiprep Solution 2 (2.2:1, Solution1:
309 Media). 1 mL Media was overlain and the gradient was spun down for 20 minutes
310 at 1000 RPM 4°C. Viable cells were collected from the top of the gradient and
311 washed twice with RPMI media. Cells were then plated in 75 cm filtered flasks with
312 PenStrep and Fungizone added to the RPMI Media. The cells were cultured for
313 approximately a week to reduce stromal cell survival and then tested for
314 mycoplasma. To generate an in vivo selected line twice, these lung metastatic 1
315 (LM1) generation cells were then re-injected at 150,000 tail vein and the process
316 was repeated.

317

318 **Chromatin Immunoprecipitation**

319 MDA-MB-231 and LM2 cells in biological replicates were plated in 15 cm plates
320 (~12 million cells). For cross-linking, 1% formaldehyde was added to cells at 37°C
321 for 10 minutes, and quenched with glycine at a final concentration of 0.14 M for 30

322 minutes at room temperature. The plates were put on ice, the media was removed
323 and cells were washed with ice cold PBS twice. 500 uL PBS with 1x HALT protease
324 inhibitors (Thermo) were added and cells were scraped and put in an Eppendorf
325 on ice. Cells were pelleted at 4000 RPM in a refrigerated centrifuge for 4 minutes.
326 The cell pellets were then resuspended in 400 uL Lysis buffer (1% SDS, 50 mM
327 Tris Hcl pH 8.0 20 mM EDTA, protease inhibitors (Roche) and incubated on ice for
328 10 minutes. Lysates were then sonicated to produce DNA fragments between 200
329 – 1000 bp with settings Amplitude 70, 10 sec on 30 sec rest for three repetitions
330 on Sonicator S-4000 (Branson) with Microtip and Ultrasonic Liquid Processor
331 (Misonix). Lysates were kept on ice during sonication to prevent protein
332 degradation. Lysates were then clarified by centrifugation at max speed at 4 °C for
333 10 minutes. Equivalent amounts of lysate were then added to separate
334 eppendorfs, saving some lysate for input samples. Either 5 ug rabbit IgG or 5ug
335 POLR3A (Cell Signaling #12825S) were then added, with a final volume of 1 ml
336 with protease inhibitors of dilution buffer (16.7 mM Tris HCl pH 8.0, 0.01% SDS,
337 1.1% Triton X-100, 1.2 mM EDTA, 167 mM NaCl). Lysate and antibody mixtures
338 were incubated overnight at 4 °C with rotation. 50 uL Protein G Dynabeads were
339 added to each sample after washing and incubated at 4 °C for 2 hours with rotation.
340 Tubes were then placed on a magnet for 2 minutes, discarding the supernatant.
341 The following washes were performed, twice each for 5 minutes at 4 °C in the
342 following order: low salt (140 mM NaCl, 50 mM HEPES, 0.1% SDS, 1% Triton X-
343 100, 0.1% deoxycholate, 1 mM EDTA) high salt (500 mM NaCl, 50 mM HEPES,
344 0.1% SDS, 1% Triton X-100, 0.1% deoxycholate, 1 mM EDTA), LiCl (250 mM LiCl,
345 20 mM Tris HCl pH 8.0, 0.5% NP-40, 0.5% deoxycholate, 1 mM EDTA) and TE
346 Buffer (10 mM Tris HCl pH 8.0, 1 mM EDTA). 100 uL Elution buffer (50 mM Tris
347 HCl pH 8.0, 1 mM EDTA) was then added to the beads and incubated overnight
348 at 65 °C on a shaker to enable elution. The eluted sample was transferred to a new
349 tube and repeated for a final volume of 200 uL per sample. 1 uL of 10 mg/mL
350 RNase A was added to each sample (including input samples) and incubated at
351 37 °C for 30 minutes. 2 uL of Proteinase K was added (10 mg/mL) and incubated
352 for 2 hours at 56 °C. DNA was then purified using the DNA Clean and Concentrator
353 Kit (Zymo Research). Enrichment of Polymerase III bound loci was confirmed with
354 genomic tRNA qPCR primers and quantified as Percent Input over IgG. The Input
355 and IP DNA samples were then PCR amplified with Illumina barcodes to construct
356 a multiplexed library. The library was quantified using TapeStation and sequenced
357 on the 50 SR HiSeq at the Rockefeller Genomics Resource Center.

358

359 **tRNA Capture qPCR**

360 tRNA quantification by RT-qPCR was performed as described previously¹. RNA
361 purified with Norgen Total Purification Kit was quantified using a Nanodrop.
362 Normalized RNA across samples was added to a hybridization mixture (final
363 concentration 10 mM Tris HCl pH 7.4, 50 mM NaCl, 1 mM EGTA pH 8.0) with 2
364 uM Hybridization probes. Hybridization probes specific for the following tRNA were
365 used: Ile TAT Left 5'
366 /5Phos/AAGTACCGCGCGCTACCGATTGCGCCACTGGAGCGATCGTCCGAC
367 TGTAGAA, Ile TAT Right 5'

368 CGTGTGCTCTTCCGATCTTGCTCCAGGTGAGGCTCGAACTCACACCTCGGC
369 ATTAT', Ile GAT Left 5'
370 /5Phos/CAGCACCACGCTCTACCAACTGAGCTAACCGGCCGATCGTCGGACT
371 GTAGAA, Ile GAT R 5'
372 CGTGTGCTCTTCCGATCTTGCCGGTGCGGGAGTCGAGCCCGCGCCTTGG
373 TGTTAT 3'. Each 'left' probe contained a 5' phosphate to enable subsequent
374 ligation. RNA and probe mixture was hybridized using a thermocycler and brought
375 to RT. 1x SplintR ligase buffer, SplintR Ligase (NEB) and RNase Inhibitor
376 (Promega) were added and incubated at room temperature for 2 hours. An
377 additional ligation step with T4 Ligase was performed overnight at 16 °C. The RNA
378 was then degraded with RNase A (Thermo Fisher) & H (NEB) for 30 minutes at 37
379 °C. The ligated probe reaction was then diluted 1:50 and quantified using primers
380 (Forward 5' CGTGTGCTCTTCCGATCT 3' & Reverse 5'
381 GATCGTCGGACTGTAGAA 3') specific to the probe backbone by RT-qPCR. 5S
382 and 18S probes were used as loading controls: 5S Left 5'
383 5PHOS/CTGCTTAGCTTCCGAGATCAGACGAGATCGGGCGCGATCGTCGGA
384 CTGTAGAA 3' 5S Right 5'
385 CGTGTGCTCTTCCGATCTCCAGGCGGTCTCCCATCCAAGTACTAACCAGGC
386 CCGACC 3' or 18S Left 5'
387 5PHOS/CCTAGTAGCGACGGGCGGTGTGTACAAAGGGCGCCGATCGTCGGA
388 CTGTAG 3' 18S Right 5'
389 CGTGTGCTCTTCCGATCTCCGATCCGAGGGCCTCACTAAACCATCCAATC 3'.
390

391 Northern Blot

392 RNA was purified using Norgen total RNA Purification kits according to
393 manufacturer's instructions. 5 ug purified RNA was run on 10% TBE-Urea gels at
394 200V for 1 hour, and transferred to a Hybond-N+ membrane (GE) at 150A for 1
395 hour. RNA was then crosslinked to the membrane at 240 mJ/cm², and blocked with
396 Oligo Hybridization Buffer (Ambion) for 1 hour at 42 °C. Northern probes were
397 labeled with ³²P ATP with T4 PNK (NEB), purified with a G25 column (GE
398 Healthcare), and hybridized in Oligo Hybridization Buffer overnight at 42 °C.
399 Membranes were washed with 2X SSC 0.1% SDS Buffer, then with 1X SSC 0.1%
400 SDS Buffer. Films were developed at varying times subject to radioactivity of
401 membrane. Probe oligo sequences for Ile TAT Intron: 5'
402 ACUGCUGUAUAAGUACCGCGCGC 3' and Ile TAT 5'
403 cucggcauuuaaguaccgcgcg 3' and U6 5' CACGAATTTGCGTGTATCCTT 3'.
404 Membranes were stripped with 0.1% SDS in boiling water and allowed to cool to
405 room temperature. Quantification was performed with ImageJ and normalized to
406 U6 levels.

407

408 RT qPCR

409 RNA was purified using the Norgen total RNA Purification kits according to
410 manufacturer's instructions. 1ug purified RNA was used for cDNA production with
411 Superscript III reverse transcriptase (Thermo Fisher Scientific) using random
412 hexamer as a template. The cDNA was diluted 1:5 and quantified with Sybr Green
413 Master Mix (Thermo). The ddCT levels were quantified through normalization to

414 18S with biological replicates. One primer set was used for tRNA^{lle}_{GAT} genetic loci
415 chr.X-6 and chr.X-7 as their sequences are indistinguishable. Primer sequences
416 are available in the Supplemental Material Section.

417

418 **tRNA Fluorescence In Situ Hybridization**

419 Breast tissue microarrays were obtained from Biomax (BC08118 & BR1005b).
420 Slides underwent deparaffination via 5 minute incubations in xylene 2x, 100%
421 Ethanol, 2x, 70% Ethanol, 50% Ethanol, and subsequently molecular grade water.
422 Antigen retrieval was performed with 1x Citrate Buffer pH 6.0 in a microwave for
423 20 minutes. Slides were cooled to room temperature, then tissue regions were
424 isolated with a PAP pen. Slides were incubated in 0.13 M 1-methylimidazole 300
425 mM NaCl pH 8.0 solution twice for 10 minutes each. Next, slides were incubated
426 with 0.16 M N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC)
427 (Sigma Aldrich) in the 1-methylimidazole solution for 1 hour at RT to preserve small
428 RNAs²¹. Slides were then washed with 0.2% Glycine in Tris buffered saline (TBS)
429 pH 7.4, then in TBS twice. Pre-hybridization of slides occurred with 1X ISH
430 (Exiqon) buffer at 53 °C for 1 hour. 40 nM tRNA double DIG labeled LNA Probe
431 targeting tRNA^{lle}_{UAU} (Sequence 5'
432 CA+GGTGAGGCTCGAACTCACAC+C+TCGGCAT+T+A 3' with +N indicating
433 LNA at that nucleotide) and tRNA^{lle}_{GAU} (Sequence 5'
434 AGTCGA+GCCCCGCGAC+CTTGG+TGTTA+T+C 3') (Qiagen) in 1X ISH buffer
435 was denatured at 95°C for 5 minutes followed by cooling on ice for 1 minute. The
436 LNA probe was added to the slide (and covered with a glass coverslip to prevent
437 evaporation) and hybridized overnight at 52 °C. Slides were then washed with 4X
438 SSC, 2X SSC, 1X SSC, and 0.5X SSC in 50% formamide for 20 minutes each,
439 then washed with 100 mM Tris-HCl pH 7.4 150 mM NaCl (TN buffer) for 5 minutes.
440 Slides were blocked with 1X Blocking Reagent (Roche) in TN buffer for 1 hour at
441 RT. Anti-DIG POD in TN blocking buffer was added 1:100 and incubated for 2 hrs.
442 Slides were washed 3x for 5 minutes in TN buffer with 0.05% Tween-20 (TNT).
443 FITC-tyramide solution 1:100 in 1x amplification reagent (TSA) was incubated on
444 slides for 10 minutes at RT. Slides were subsequently washed 3x for 5min with
445 TNT buffer. Samples were washed with PBS and stained with DAPI for 5 minutes,
446 then mounted with Prolong Gold anti-fade solution (Thermo Fisher). Fluorescent
447 intensity was measured on an Inverted TCS SP8 laser scanning confocal
448 microscope (Leica) at the Bioimaging Resource Center at Rockefeller University
449 and quantified by mean fluorescence intensity relative to DAPI. Quantification was
450 performed blind.

451

452 **Viral Production & Stable Cell Line Generation**

453 Stable generation of cell lines was performed as previously described^{1,6,7}.
454 Lentivirus was generated using the ViraSafe lentiviral packaging system (Cell
455 Biolabs) with Lipofectamine 2000 (Invitrogen) in HEK293T cells. Transductions
456 were performed with 8 ug/mL polybrene. Plasmids to overexpress tRNA^{lle} or with
457 shRNAs targeting tRNA^{lle}_{GAU} were cloned into the plko.1 puromycin (Addgene #
458 8453) or blasticidin (Addgene #26655) backbone with AgeI/EcoRI restriction
459 sites^{22,23}. CRISPRi stable cells lines were generated with lentiviral transduction of

460 dCas9-KRAB (Addgene # 110820) and pSLQ plasmid (Addgene # 51024) cloned
461 with a tRNA^{lle}_{GAU} targeting guide (5' TGAGCTAACCGGCCCGCCCGA 3'), and then
462 flow sorted for positive BFP+ and mCherry+ cells^{24,25}. CRISPR generated cells
463 were transduced with lentiCRISPRv2 (Addgene # 98290) cloned with specific
464 guides targeting tRNA^{lle}_{UAU} loci (Guide 1: 5' GCGCTAACCGATTGCGCCAC 3',
465 Guide 2: 5' TGGCGCAATCGGTTAGCGCG 3') or the eGFP targeting sequence
466 as control (5' GGGGCGAGGAGCTGTTACCG 3'). Cells were then either
467 selected with 2 ug/mL puromycin or 7.5 ug/mL Blasticidin (Thermo Fisher
468 Scientific).

469

470 **Animal Studies**

471 For metastasis assays, tail veins injections were performed in 5-6 week age
472 matched female NOD SCID Gamma mice (The Jackson Laboratory #005557).
473 Cells were counted via hemacytometer and resuspended in 1x PBS, and 100uL
474 was injected with a 27G ½ needle (BD) into the lateral tail vein. Non-invasive
475 bioluminescence imaging was performed immediately after injections using an
476 IVIS Lumina II (Caliper Life Science) for Day 0 baseline, followed by weekly
477 imaging. Bioluminescence imaging was obtained through retro-orbital injection of
478 50uL D-luciferin (Perkin Elmer) followed by 1 minute exposure in IVIS Lumina II.
479 Unless otherwise stated, each experimental group consisted of n=5 mice. For
480 bioluminescence imaging, cell lines were transduced with triple reporter and FACS
481 sorted for GFP positive cells 48hours post transduction^{4,10}. All animal work was
482 conducted in accordance with protocols approved by the Institutional Animal Care
483 and Use Committee at The Rockefeller University.

484

485 **Histology**

486 Lungs were prepared by perfusion fixation with 4% paraformaldehyde through
487 the circulation via the right ventricle post euthanasia. Lungs were then fixed in
488 4% paraformaldehyde overnight at 4°C. The samples were then embedded in
489 paraffin and sectioned in 5 µm slices that were used for immunostaining. 5 µm
490 sections at different depths were stained with hematoxylin and eosin (H&E).

491

492 **Ribosomal Profiling**

493 Ribosomal profiling was performed based on the McGlincy & Ingolia protocol⁴.
494 Briefly, cells were plated in 15 cm dishes at 50% confluency the day before
495 collection. The media was aspirated, and the cells were washed with 5 mL ice cold
496 PBS, and aspirated. The plate was then submerged in liquid nitrogen to freeze the
497 cells. 400 uL ice cold lysis buffer was added to the plate, and scraped immediately.
498 Each lysate was kept on ice until all plates were collected. Several plates were
499 combined with lysis buffer totaling 1 mL per biological replicate. Lysates were then
500 triturated ten times with a 26 gauge needle. Lysates were clarified at top speed for
501 10 mins in a cold bench top centrifuge and the supernatant was recovered and
502 snap frozen in liquid nitrogen, then stored at -80 °C. Lysates were quantified with
503 Quant-iT Ribogreen assay (Life Technologies) and 60 ug total RNA per sample
504 was incubated with 3 uL RNase I (Epicentre #N6901K) for 45 minutes at RT with
505 light shaking. 10 uL SUPERase*In RNase Inhibitor (Invitrogen) was added to stop

506 digestion, and the RNA was transferred to a 13 mm x 51 mm polycarbonate
507 ultracentrifuge tube. 900 uL Sucrose cushion (1 M Sucrose with 20 U/mL
508 SUPERase*In in polysome buffer⁴) was underlaid and spun at 100,000 RPM at
509 4°C for 1 hour. With ribosomes pelleted, the supernatant was pipetted out of the
510 tube. 300 uL Trizol was added to the pellet and resuspended. RNA was
511 subsequently purified with the Direct-zol kit (Zymo). RNA was then precipitated
512 overnight and resuspended after ethanol washes in 5 uL 10 mM Tris HCl pH 8.0.
513 Ribosome footprints were isolated after running a 15% TBE-Urea gel and the RNA
514 was excised within the range of 17nt – 34nt and then precipitated overnight. RNA
515 fragments were then dephosphorylated with T4 PNK and ligated to a DNA linker
516 with T4 Rnl2(tr) K227Q (NEB #M0351S) for 3 hours with distinct linker barcodes.
517 Unligated linkers were depleted with yeast 5'-deadenylase (NEB #M0331S) and
518 RecJ exonuclease (Epicentre #RJ411250) at 30°C for 45 minutes. Ligations were
519 then purified with the Oligo Clean & Concentrator kit (Zymo) and samples were
520 pooled. Ribo Zero Gold was then used to deplete ribosomal RNAs (2 reactions
521 were used, and the 50°C step was omitted, Illumina). RNA was then purified using
522 Oligo Clean & Concentration kit. The pooled ligations were then reverse
523 transcribed using Superscript III at 55°C for 30 minutes, with RNA templates
524 hydrolyzed by 2.2 uL 1 M NaOH. Samples were purified with the Oligo Clean &
525 Concentrator kit and run on a polyacrylamide gel and the RT product was excised
526 above 76nt. Gel slices were incubated with DNA gel extraction buffer overnight
527 after the gel was broken up with gel breaker tubes (IST Engineering) and
528 precipitated overnight. The RT product was resuspended in 10mM Tris HCl pH 8.0
529 and circularized with CirLigase II at 60°C for 1 hour. qPCR quantification of
530 circularization products were performed to quantify number of cycles sufficient for
531 library preparation, with the concentration estimated at 713 pM. 8 cycles were used
532 to amplify the library with Pfusion with the primers indicated, NI-799 and NI-798⁴.
533 Products were purified and size selected at >136bp, primarily at 160bp. The library
534 was then precipitated, quality checked with TapeStation and sequenced on the
535 NextSeq High Output 75 Single Read at the Rockefeller University Genomics
536 Resource Center. Concurrently 1 ug total RNA was prepped for RNA sequencing
537 according to the manufacturer's instructions (Illumina). Analysis was performed as
538 described previously¹. For analysis, reads were first subjected to linker removal
539 and quality trimming (cutadapt v1.14). The reads were then aligned against a
540 reference database of rRNAs (iGenomes: AbundantSequences) and tRNAs
541 (GtRNAdb, hg38) so as to remove contaminants (using bowtie 2.3.4.1). STAR
542 v2.5.2a was then used to align the remaining reads to the human transcriptome
543 (build hg38). Xtail was used to count ribosome protected fragments, estimate
544 translation efficiency, and perform statistical comparisons²⁶.

545

546 **Polysome Profiling**

547 Polysome profiling was adapted from Gandin et. al.'s protocol and with direction
548 and assistance from Dr. Alison Ashbrook in Dr. Charlie Rice's laboratory²⁷. The
549 day before cell collection, 7.5 million MDA-231 were plated in 15 cm plates (2
550 plates per experimental biological replicate) in normal DMEM media supplemented
551 with 10% FBS. Cells were plated to achieve approximately 80% confluency at

552 collection time to optimize polysome content. Each plate was treated for 5 minutes
553 at 37 °C with DMEM with 100 ug/mL cycloheximide. The plate was then transferred
554 to ice and the cycloheximide media was aspirated. Cells were washed twice with
555 ice cold 1x PBS with 100ug/mL cycloheximide. All PBS was then aspirated
556 carefully and the 15 cm plate was flash frozen in liquid nitrogen. 425 uL Lysis Buffer
557 (5 mM Tris HCl pH 7.5, 2.5 mM MgCl₂, 1.5 mM KCl, 100 ug/mL cycloheximide, 2
558 mM DTT, 0.5% Triton X-100, 0.5% sodium deoxycholate, and 100 units of
559 SUPERase*In RNase Inhibitor (Invitrogen) 1x Protease Inhibitors EDTA-free) was
560 then added to the plate and cells were scraped and transferred to an eppendorf
561 tube on ice. Lysates were then spun at high speed at 4°C for 7 minutes to pellet
562 nuclei. Supernatant was transferred to a new tube and the RNA concentration was
563 measured using the Quant-iT Ribogreen assay (Life Technologies). 64ug RNA
564 lysate was used for polysome fractionation. 10-50% Sucrose gradients were
565 prepared the day before ultracentrifugation. Ultracentrifuge polyallomer tubes
566 (Beckman Coulter, Cat #331372) were marked halfway and ~5.5 mL 10% sucrose
567 polysome gradient buffer (20 mM Tris HCl pH 7.5, 140 mM KCl, 5 mM MgCl₂, 10%
568 Sucrose, 100 ug/mL cycloheximide, 0.5 mM DTT, 20 U/mL SUPERase*In) was
569 added with a 10 mL sterile syringe to 1/8 inch above the line. 50% sucrose
570 polysome gradient buffer (20 mM Tris HCl pH 7.5, 140 mM KCl, 5 mM MgCl₂, 50%
571 Sucrose, 100 ug/mL cycloheximide, 0.5 mM DTT, 20 U/mL SUPERase*In) was
572 then underlain until the 10% sucrose layer was pushed above the marked line. The
573 syringe was wiped with a Kimwipe prior to addition of 50% sucrose buffer to
574 maintain separation between buffers. Black caps were added carefully to prevent
575 the accumulation of bubbles in each ultracentrifuge tube. The Biocomp gradient
576 master was then used at the following conditions: Long Cap 10% - 50% WV Step
577 1, 1:50 minutes, 80° angle, 21 speed. Gradients were then sealed with parafilm
578 and incubated at 4°C overnight. Gradients were then balanced to within 10mg of
579 each other. Normalized cell lysates were added (500 uL volume) and spun in a
580 SW41 ultracentrifuge rotor at 38,000 RPM for 2 hours at 4°C. 60% sucrose was
581 then used to fractionate spun lysates into 1 mL fractions and polysome peaks were
582 measured with a Combi Flash UV-vis detector (Brandel) and TracerDAQ software.
583 Polysome fractions were then pooled into appropriate groups: highly translated
584 (Higher than 3 ribosomes, past the 1st peak), and lowly translated (1-2 ribosomes
585 and 80s) based on A280 UV peaks. The pooled fractions were then incubated with
586 3:1 Trizol LS Reagent, vortexed thoroughly, and incubated at RT for 5 minutes.
587 RNA was then extracted following the instructions of the Direct-zol Miniprep Ki
588 (Zymo Research), and eluted in 50 uL. RNA was quantified and normalized for
589 input into either tRNACapture-seq qPCR with 5S, tRNA^{lle}_{GAU}, or tRNA^{lle}_{UAU} probes
590 (250 ng) or as Input into the QuantSeq 3' mRNA-Seq Library Prep Kit (Lexogen)
591 kit. 500 ng RNA was used as input and samples were processed according to
592 QuantSeq (Lexogen) instructions. A pooled library was compiled using
593 manufacturer's primers and 10 nM Pool was quality checked with TapeStation and
594 sequenced on the NextSeq High Output 75 Single Read at the Rockefeller
595 University Genomics Resource Center.
596 For analysis, reads were mapped to the human transcriptome using STAR
597 (v2.5.2a) with genome build hg38 and the number of reads for each gene was

598 tabulated using featureCounts (v1.6.1). The Bioconductor package DESeq2 was
599 then used to compare the fractions in control and tRNA^{lle}_{GAU}/tRNA^{lle}_{UAU} modulated
600 samples.

601

602 **Proteomics**

603 Cells were lysed in 20 mM Tris HCl pH 8.0, 1% NP-40, 2 mM EDTA with 1x
604 protease inhibitors (Roche). 50 ug lysate was used for label free quantification at
605 the Rockefeller University Proteomics Core Facility. Maxquant software was
606 utilized to compare three replicates per experimental group. Label free quantitation
607 (LFQ) was used to compare the same peptide/protein between experimental
608 groups (n=3 samples per group), which relies on normalization and strict filter
609 criteria determined by the Proteomics Core. Student's t-test difference and
610 student's t-test was then used to analyze the data.

611

612 **Immunofluorescence**

613 Paraffin embedded histology slides from metastatic nodules were used. Slides
614 underwent deparaffination via 5 minute incubations in xylene 2x, 100% Ethanol,
615 2x, 70% Ethanol, 50% Ethanol, and subsequently 1x PBS. Antigen retrieval was
616 performed with 1x Citrate Buffer pH 6.0 in a microwave for 20 minutes. Slides were
617 cooled to room temperature, then tissue regions were isolated with a PAP pen.
618 Slides were then blocked with 10% Goat Serum (Sigma Aldrich) for 30 minutes at
619 room temperature. Primary antibodies were incubated overnight at 4°C in a moist
620 chamber (Vimentin V9 mouse (Abcam ab8069) 1:50), or for 2 hours at room
621 temperature (Ki67 (Abcam ab927420) 1:200). Slides were washed with 0.5%
622 Tween 20 PBS then incubated with secondary antibody for 1 hour at RT (1:200).
623 Slides were then stained with DAPI for 5 minutes, and sealed with Prolong Gold
624 anti-fade solution (Thermo Fisher). Fluorescent intensity was measured on an
625 Inverted TCS SP8 laser scanning confocal microscope (Leica) at the Bioimaging
626 Resource Center at Rockefeller University and quantified by number of positive
627 cells per field of view. Quantification was performed blind.

628

629 **In Vitro Growth Assays**

630 Cells at similar confluencies were resuspended in new DMEM media and counted
631 with a hemacytometer. Cells were then seeded in equal numbers (100K for stress
632 conditions, 50K for normal in vitro conditions) in 6 well plates in triplicate. Cells
633 were then counted at the endpoint day with a hemacytometer. Each experiment
634 was conducted three times. Cells treated with 200 uM H2O2 were counted on Day
635 3. Cells exposed to 0.5% hypoxia in an Invivo² chamber (Baker Ruskinn) were
636 quantified on Day 3. Growth assays in normal *in vitro* conditions were quantified
637 on Day 5.

638

639 **Western Blot**

640 Cells seeded a day previously were washed with 1x PBS and then lysed with either
641 RIPA buffer or 20 mM Tris HCl pH 8.0, 1% NP-40, 2 mM EDTA with 1x protease
642 inhibitors (Roche). Protein concentrations were quantified with a BCA Kit (Thermo
643 Fisher) and normalized. Protein lysates were run at 200V for an hour through either

644 a 4-12% Bis-Tris or 3-8% Tris Acetate gel (Invitrogen), and then transferred at 300
645 mA for one hour in 15% methanol 1x Transfer Buffer on a methanol activated
646 PVDF membrane. Membranes were then stained with Ponceau and blocked for
647 one hour in Odyssey® Blocking Buffer. Primary antibody incubations occurred
648 overnight at 4°C on a rocker at the following concentrations: alpha tubulin 1:1000,
649 (Proteintech) SMNDC1 1:500 (Proteintech). Membranes were then washed with
650 0.05% Tween 20 PBS three time and incubated with mouse or rabbit fluorescent
651 IRDye® conjugated secondary antibodies 1:20,000 (LI-COR Biosciences) for one
652 hour. Membranes were subsequently washed three times and imaged and
653 quantified using the Odyssey® Sa Infrared Imaging System at the Rockefeller
654 University Center for High Throughput Screening. Quantification was done using
655 the Image Studio Lite™ software.

656

657 **Codon Reporters**

658 Wildtype or codon mutant SMNDC1 (all AUA codons changed to AUC codons)
659 coding sequence gene blocks were designed with NheI & XhoI restriction sites and
660 a N-terminal flag tag and ordered from IDT. SMDNC1 gene blocks were cloned
661 into the psiCheck 2 vector. The firefly luciferase was removed and replaced with a
662 renilla luciferase with only AUU encoding isoleucines via restriction cutting with
663 PspOMI & XbaI. This adapted SMNDC1 reporter was transfected with 2.5 ug
664 plasmid and 10 uL Lipofectamine 2000 (Thermo Fisher) in triplicate in MDA-MB-
665 231 cells with modulated tRNA^{le} levels. Cells were lysed after 24 hours and protein
666 was extracted with RIPA buffer with 1x protease inhibitors EDTA-free (Roche).
667 Protein expression was measured through LICOR Western blotting as described
668 above.

669

670 **RSCU and Pathway Enrichment Analyses**

671 Gene filtering: The Homo sapiens GRCh38 CDS sequences were downloaded
672 from the Ensembl database. To avoid multiple splice variants from the same gene
673 affecting downstream analysis, principle splice isoforms were filtered using
674 annotations from the APPRIS database and a custom Python script. For genes
675 with multiple annotated isoforms, the transcript with the highest score was chosen
676 as the representative.

677 RSCU calculation: To calculate the relative synonymous codon usage (RSCU) for
678 a given codon in each gene, we first calculated the total abundances of each codon
679 across our entire filtered CDS dataset to determine the empiric distribution of
680 synonymous codon usage for each amino acid. For each gene, the RSCU score
681 was calculated as: $[\text{Observed_Codon_Usage} - \text{Expected_Codon_Usage}] /$
682 $\text{Expected_codon_usage}$. The expected codon usage was defined as
683 $\text{Observed_Amino_Acid_Usage} * \text{Pr}(\text{Codon_Usage} | \text{Amino_Acid})$ where the
684 probability mass function was determined using the empiric codon distribution
685 described above. For genes/transcripts in which a given amino acid appeared zero
686 times, the RSCU score was set to 0.

687 Mutual Information/Pathway Enrichment: Genes were ranked by the RSCU score
688 calculated above. Mutual information analyses to detect significantly over-
689 represented and under-represented pathways in discrete bins were performed

690 using the iPAGE mutual information framework with pathway annotations built from
691 the Reactome database²⁸. Heatmaps were generated with iPAGE. To determine
692 pathways that were most likely to be divergently modulated by AUA or AUC
693 over/under-expression, we additionally filtered the output to include pathway
694 enrichments/depletions present in both AUC and AUA analyses with p-values less
695 than 10E-3 in the highest RSCU bin. Heatmaps were generated using Python
696 software and the seaborn package.

697 Databases/Sites/Software used:

698 Ensembl: <https://useast.ensembl.org/index.html>

699 APPRIS: <http://appris-tools.org/#/>

700 iPAGE: <https://tavazoielab.c2b2.columbia.edu/iPAGE/>

701 Reactome: <https://reactome.org>

702 Python 3.6.0: <https://www.python.org>

703 Pandas: <https://pandas.pydata.org>

704 Seaborn: <https://seaborn.pydata.org>

705

706 **Statistical analysis**

707 Results are presented in dot-plot with dots representing individual values and bar-
708 charts depicting average values with standard error of the mean (\pm s.e.m.). The
709 number of samples for each group was chosen based on the expected levels of
710 variation and consistency. FISH quantification was performed in a blinded fashion.
711 Unless otherwise stated, statistical significance was assessed by a two-tailed
712 Student's t-test with P -value < 0.05 being considered statistically significant.

713

714 **Data availability**

715 Experimental data will be available from the corresponding author upon request.
716 Sequencing data will be made available in public databases.

717

718 **Ethical regulations**

719 All animal experiments were performed under supervision and approval of the
720 Institutional Animal Care and Use Committee (IACUC) at the Rockefeller
721 University.

722 **Acknowledgements** We thank members of the Tavazoie laboratory and Hani
723 Zaher for thoughtful comments on previous versions of the manuscript. We thank
724 Alison Ashbrook and Charlie Rice's laboratory for technical assistance with
725 polysome profiling. We also thank Rockefeller University resource centers: Alison
726 North and staff at the Bio-Imaging resource facility, Connie Zhao from the
727 genomics resource center, Soren Heissel and Henrik Molina from the proteomics
728 resource center, and Vaughn Francis from the Comparative bioscience center and
729 veterinary staff for animal husbandry and care. L.N and M.C.P. were supported by
730 a Medical Scientist Training Program grant from the National Institute of General
731 Medical Sciences of the National Institutes of Health under award number
732 T32GM007739 to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional
733 MD-PhD program. H.G. was supported by R00CA194077 and R01CA24098.
734 S.F.T. is an HHMI Faculty Scholar, and was supported by the Breast Cancer

735 Research Foundation award, the Reem-Kayden award, and by NCI grant
736 R01CA215491. S.F.T. and the Tavazoie lab were supported by the Black Family
737 and the Black Family Metastasis Research Center.

839

840 **Author Contributions** L.N., H.G. and S.F.T. designed the experiments. L.N, N.M.,
841 and M.C.P. performed the experiments. H.G. and H.A. performed ChIP-Seq,
842 TGIRT, Ribosomal Profiling, Polysome Profiling sequencing, and ribosomal
843 dwelling time analyses. D.H. performed iPAGE codon analyses. L.N. and S.F.T.
844 wrote the paper with input from the co-authors.

845


846 **References**

847

848

- 849 1 Ogle, J. M., Carter, A. P. & Ramakrishnan, V. Insights into the decoding
850 mechanism from recent ribosome structures. *Trends Biochem Sci* **28**, 259-266,
851 doi:10.1016/S0968-0004(03)00066-5 (2003).
- 852 2 Schmeing, T. M. & Ramakrishnan, V. What recent ribosome structures have
853 revealed about the mechanism of translation. *Nature* **461**, 1234-1242,
854 doi:10.1038/nature08403 (2009).
- 855 3 Pavon-Eternod, M. *et al.* tRNA over-expression in breast cancer and functional
856 consequences. *Nucleic Acids Res* **37**, 7268-7280, doi:10.1093/nar/gkp787
857 (2009).
- 858 4 Goodarzi, H. *et al.* Modulated Expression of Specific tRNAs Drives Gene
859 Expression and Cancer Progression. *Cell* **165**, 1416-1427,
860 doi:10.1016/j.cell.2016.05.046 (2016).
- 861 5 Gingold, H. *et al.* A dual program for translation regulation in cellular
862 proliferation and differentiation. *Cell* **158**, 1281-1292,
863 doi:10.1016/j.cell.2014.08.011 (2014).
- 864 6 Robichaud, N., Sonenberg, N., Ruggero, D. & Schneider, R. J. Translational
865 Control in Cancer. *Cold Spring Harb Perspect Biol* **11**,
866 doi:10.1101/cshperspect.a032896 (2019).
- 867 7 Vo, M. N. *et al.* ANKRD16 prevents neuron loss caused by an editing-defective
868 tRNA synthetase. *Nature* **557**, 510-515, doi:10.1038/s41586-018-0137-8
869 (2018).
- 870 8 Knott, S. R. V. *et al.* Asparagine bioavailability governs metastasis in a model of
871 breast cancer. *Nature* **554**, 378-381, doi:10.1038/nature25465 (2018).
- 872 9 Loayza-Puch, F. *et al.* Tumour-specific proline vulnerability uncovered by
873 differential ribosome codon reading. *Nature* **530**, 490-494,
874 doi:10.1038/nature16982 (2016).
- 875 10 Minn, A. J. *et al.* Genes that mediate breast cancer metastasis to lung. *Nature*
876 **436**, 518-524, doi:10.1038/nature03799 (2005).
- 877 11 Goodarzi, H., Elemento, O. & Tavazoie, S. Revealing global regulatory
878 perturbations across human cancers. *Mol Cell* **36**, 900-911,
879 doi:10.1016/j.molcel.2009.11.016 (2009).

- 880 12 McGlincy, N. J. & Ingolia, N. T. Transcriptome-wide measurement of translation
881 by ribosome profiling. *Methods* **126**, 112-129,
882 doi:10.1016/j.ymeth.2017.05.028 (2017).
- 883 13 Gill, J. G., Piskounova, E. & Morrison, S. J. Cancer, Oxidative Stress, and
884 Metastasis. *Cold Spring Harb Symp Quant Biol* **81**, 163-175,
885 doi:10.1101/sqb.2016.81.030791 (2016).
- 886 14 Loo, J. M. *et al.* Extracellular metabolic energetics can promote cancer
887 progression. *Cell* **160**, 393-406, doi:10.1016/j.cell.2014.12.018 (2015).
- 888 15 Nguyen, A., Yoshida, M., Goodarzi, H. & Tavazoie, S. F. Highly variable cancer
889 subpopulations that exhibit enhanced transcriptome variability and
890 metastatic fitness. *Nat Commun* **7**, 11246, doi:10.1038/ncomms11246 (2016).
- 891 16 Piskounova, E. *et al.* Oxidative stress inhibits distant metastasis by human
892 melanoma cells. *Nature* **527**, 186-191, doi:10.1038/nature15726 (2015).
- 893 17 Katibah, G. E. *et al.* Broad and adaptable RNA structure recognition by the
894 human interferon-induced tetratricopeptide repeat protein IFIT5. *Proc Natl*
895 *Acad Sci U S A* **111**, 12025-12030, doi:10.1073/pnas.1412842111 (2014).
- 896 18 Mohr, S. *et al.* Thermostable group II intron reverse transcriptase fusion
897 proteins and their use in cDNA synthesis and next-generation RNA
898 sequencing. *RNA* **19**, 958-970, doi:10.1261/rna.039743.113 (2013).
- 899 19 Goodarzi, H. *RiboLog*, <github.com/Goodarzilab/Ribolog> (2019).
- 900 20 Nguyen, A. *et al.* PKLR promotes colorectal cancer liver colonization through
901 induction of glutathione synthesis. *J Clin Invest* **126**, 681-694,
902 doi:10.1172/JCI83587 (2016).
- 903 21 Chaudhuri, A. D., Yelamanchili, S. V. & Fox, H. S. Combined fluorescent in situ
904 hybridization for detection of microRNAs and immunofluorescent labeling for
905 cell-type markers. *Front Cell Neurosci* **7**, 160, doi:10.3389/fncel.2013.00160
906 (2013).
- 907 22 Stewart, S. A. *et al.* Lentivirus-delivered stable gene silencing by RNAi in
908 primary cells. *RNA* **9**, 493-501 (2003).
- 909 23 Bryant, D. M. *et al.* A molecular network for de novo generation of the apical
910 surface and lumen. *Nat Cell Biol* **12**, 1035-1045, doi:10.1038/ncb2106 (2010).
- 911 24 Chen, B. *et al.* Dynamic imaging of genomic loci in living human cells by an
912 optimized CRISPR/Cas system. *Cell* **155**, 1479-1491,
913 doi:10.1016/j.cell.2013.12.001 (2013).
- 914 25 Yeo, N. C. *et al.* An enhanced CRISPR repressor for targeted mammalian gene
915 regulation. *Nat Methods* **15**, 611-616, doi:10.1038/s41592-018-0048-5
916 (2018).
- 917 26 Xiao, Z., Zou, Q., Liu, Y. & Yang, X. Genome-wide assessment of differential
918 translations with ribosome profiling data. *Nat Commun* **7**, 11194,
919 doi:10.1038/ncomms11194 (2016).
- 920 27 Gandin, V. *et al.* nanoCAGE reveals 5' UTR features that define specific modes
921 of translation of functionally related MTOR-sensitive mRNAs. *Genome Res* **26**,
922 636-648, doi:10.1101/gr.197566.115 (2016).
- 923 28 Goodarzi, H., Hottes, A. K. & Tavazoie, S. Global discovery of adaptive
924 mutations. *Nat Methods* **6**, 581-583, doi:10.1038/nmeth.1352 (2009).
- 925



926


927 **Figure 1 – Isoleucine isoacceptors are differentially modulated in isogenic**
 928 **poorly and highly metastatic breast cancer pairs.**

929 (a) Volcano plot representing log₂ fold change vs. -log p value of POLR3A CHIP
 930 sequencing analysis of MDA-LM2 cells vs. MDA-MB-231 Parental cells.

931 (b) tRNA^{Ile}_{UAU} quantification by specific tRNA^{Ile}_{UAU} probe RT-qPCR normalized to
 932 18S probes of highly metastatic LM2 lines relative to their parental MDA-MB-231

933 and HCC1806 cell lines.

934 (c) tRNA^{lle}_{GAU} quantification by specific tRNA^{lle}_{GAU} probe RT-qPCR normalized to
935 18S probes of highly metastatic LM2 lines relative to the parental MDA-MB-231
936 cell line.
937 (d,e) Relative pre-tRNA abundance of tRNA^{lle}_{UAU} and tRNA^{lle}_{GAU} across multiple
938 primers covering distinct genetic loci using RT-qPCR of MDA-LM2 vs. MDA-MB-
939 231 (d) & HCC1806-LM2C vs. HCC1806 Parental cells (e).
940 (f) Relative tRNA^{lle}_{UAU}/tRNA^{lle}_{GAU} ratios quantified by fluorescent intensity
941 normalized to DAPI of breast tissue microarrays, stratified by normal tissue or
942 breast cancer stage I & II, III, measured by FISH with LNA targeting tRNA^{lle}_{UAU} or
943 tRNA^{lle}_{GAU}. Two-sided un-paired student's t-tests performed, p-values p<0.05,
944 p<0.01, p<0.001 represented as *, **, ***, respectively.
945
946




947 **Figure 2 – tRNA^{Ile}_{UAU} promotes & tRNA^{Ile}_{GAU} suppresses metastatic**
 948 **colonization .**

949 (a-b) Bioluminescent imaging post tail vein injection of 1×10^5 of MDA Parental (a)
 950 or 1.5×10^5 HCC1806 (b) cells overexpressing tRNA^{Ile}_{UAU} or control with
 951 representative lung histology stained with H&E; n=5 in each cohort.

952 (c) Quantification of lung metastatic nodules post extraction after tail vein injection
 953 of 5×10^4 LM2 CRISPR cells guides targeting eGFP or tRNA^{Ile}_{UAU}, with
 954 representative histology for control & tRNA^{Ile}_{UAU} guide 1; n=5 in each cohort.

955 (d) Bioluminescence imaging after tail vein injection of 1×10^5 of MDA LM2 cells
956 overexpressing tRNA^{lle}_{GAU} or control with representative images; luminescence
957 expressed as Radiance p/sec/cm²/sr; n=5 in each cohort.
958 (e,f) Same as (d) with MDA Parental CRISPRi cells with guides targeting either
959 control or tRNA^{lle}_{GAU} (e) or shRNA targeting control or tRNA^{lle}_{GAU} with representing
960 H&E lung histology (f). Statistics utilized include 2-way ANOVA for imaging and
961 two-sided unpaired student's t-test for nodule quantification, p-values p<0.05,
962 p<0.01, p<0.001 represented as *, **, ***, respectively.
963
964
965
966
967
968
969



970

971 **Figure 3 - Cell Cycle and Response to Stress gene expression and**
972 **phenotypes characterize tRNA^{Ile} modulations.**

973 (a,b) Reactome pathways significantly enriched in AUA (a) or AUC (b) by relative
974 synonymous codon usage (RSCU) using iPAGE.


975 (c,d) GO function terms for positive and significant TE changes from ribosomal
976 profiling (c) or label free quantification by mass spectrometry (d) in tRNA^{Ile}_{GAU}
977 depletion and tRNA^{Ile}_{UAU} overexpression cells versus control.

978 (e) Quantification of Ki67 immunofluorescence staining in MDA MB 231 tRNA^{Ile}_{GAU}
979 depletion and tRNA^{Ile}_{UAU} overexpression cells versus control.

980 (f,g) Relative cell counts of MDA MB 231 control & tRNA^{Ile}_{GAU} depletion tRNA^{Ile}_{UAU}
981 overexpression cells exposed to 0.5% hypoxia (f) or treated with 200uM H₂O₂ (g)

982 for 3 days.

983 (h) Venn Diagram of overlapping datasets to identify downstream effectors –
984 includes high RSCU tRNA^{Ile}_{UAU} score (top 50%), and genes with significantly
985 positive changes in TE and proteomics in both MDA LM2 vs. MDA Parental cells
986 and tRNA^{Ile}_{GAU} depletion tRNA^{Ile}_{UAU} overexpression cells vs. control.
987 (i) Relative cell count of MDA tRNA^{Ile}_{GAU} depletion tRNA^{Ile}_{UAU} overexpression cells
988 treated with control or SMNDC1 siRNA in 0.5% hypoxia for 2 days (d). Western
989 performed on siRNA cells on day 3.
990 (j) Relative cell counts of MDA tRNA^{Ile}_{GAU} depletion tRNA^{Ile}_{UAU} overexpression
991 cells treated with control or LSM6 siRNA for 3 days.
992 (k) Relative cell counts of MDA tRNA^{Ile}_{GAU} depletion tRNA^{Ile}_{UAU} overexpression
993 cells transduced with shRNA targeting either control or PYCARD for 3 days.
994 (l,m) LICOR Western quantification of either Flag tagged wildtype (l) or all AUA to
995 AUC codons (m) SMNDC1 expression relative to reporter control luciferase (all Ile
996 AUU) 24 hours post transfection in either MDA control or tRNA^{Ile}_{GAU} depletion
997 tRNA^{Ile}_{UAU} overexpression cells. Representative images below. Statistics utilized
998 include two-sided un-paired student's's t-tests performed, p-values *, **, ****
999 indicated as p<0.05, p<0.01, and p<0.0001, respectively.
1000
1001
1002
1003
1004
1005



1006

1007

1008

Figure 4 – Translational efficiency of AUA enriched transcripts is dependent on tRNA^{Ile}_{GAU} abundance.

1009

(a) Genes with a high abundance of AUA codons (using RSCU scores) were significantly enriched among genes upregulated in polysomes (corrected for their transcript changes) in tRNA^{Ile}_{GAU} depleted tRNA^{Ile}_{UAU} overexpression cells versus control MDA-MB-231 cells. The statistical significance of these enrichments was assessed using mutual-information calculations and associated Z score (based on randomized input vectors) and robustness scores (based on jackknifing tests). The heatmap was generated using the $-\log$ of the hypergeometric p-value for enrichment and log of p-value for depletion (collectively termed the enrichment score). The red and dark-blue borders indicate the statistical significance of the calculated hypergeometric p-values (for details, see Goodarzi et al., 2009)¹¹.

1018

1019

(b) Same as (a) except analyzed for AUC codon enrichment, showing significantly depletion among genes upregulated in polysomes (corrected for their transcript changes) in tRNA^{Ile}_{GAU} depleted tRNA^{Ile}_{UAU} overexpression cells versus control MDA-MB-231 cells.

1020

1021

1022


(c) Ribosomal AUA codon dwelling times as estimated by CELP bias coefficients (higher bias coefficient indicates longer dwelling time). Univariate regression coefficients estimating the effects of tRNA^{Ile} modulated MDA cells. A 95%

1023

1024

1025

1026 confidence interval excluding zero (not overlapping the vertical line $x=0$) means
1027 that the tested effect was significant at $\alpha=0.05$ ($p<0.05$).
1028 (d) Hypergeometric distribution shown as a z- score of AUA codon enrichment of
1029 polysome transcripts represented as log2 fold change of tRNA^{Ile}_{GAU} depleted
1030 tRNA^{Ile}_{UAU} overexpression cells versus tRNA^{Ile}_{GAU} depleted MDA MB 231 cells,
1031 stratified in bins of 10, increased log2 fold change from left to right. AUA codon
1032 representation visualized as a value ranging from -10 to 10 relative to the average.
1033 (e) Same as (d) except analyzed for AUC codon enrichment.
1034 (f) Ribosome abundance of tRNA^{Ile} quantified by specific tRNA^{Ile}_{GAU} (left) and
1035 tRNA^{Ile}_{UAU} (right) probes. RT-qPCR normalized to 5S probes of tRNA^{Ile} modulated
1036 MDA cells from polysome fractions, measured as % Input.
1037 (g) Ribosomal ratio of tRNA^{Ile}_{UAU}/ tRNA^{Ile}_{GAU} abundance quantified by specific
1038 tRNA^{Ile}_{GAU} probe and tRNA^{Ile}_{UAU} probe RT-qPCR normalized to 5S probes of
1039 tRNA^{Ile} modulated MDA cells from polysome fractions, measured as % Input.
1040 (h) Model depicting how tRNA^{Ile} abundance shifts alter translational dynamics and
1041 metastatic phenotypes. Two-sided un-paired student's's t-tests performed, p-
1042 values represented as *, ** as $p<0.05$, $p<0.01$ respectively.
1043



1044 **Supplementary Figure 1 – POLR3A ChIP sequencing reveals differential**
 1045 **occupancy in isogenic poorly and highly metastatic breast cancer pairs.**
 1046 (a) tRNA genomic loci abundance measured as percent (%) input using RT-qPCR
 1047 of POLR3A IP cDNA with GAPDH as a negative control.

1048 (b) Motif analysis of POLR3A IP normalized to Input sequences using FIRE
1049 analysis.


1050 (c) Quantification of lung metastatic nodules post extraction after tail vein injection
1051 of 1.5×10^5 HCC1806 Parental or highly metastatic derivatives LM2B or LM2C, with
1052 representative histology; n=3-4 in each cohort.

1053 (d) Northern blot quantification of $\text{tRNA}^{\text{Ile}}_{\text{UAU}}$ relative to U6 of two independently
1054 derived LM2 lines relative to HCC1806 Parental cells with representative blot.

1055 (e) Relative genomic copy number of tRNA^{Ile} loci, quantified by RT-qPCR.

1056 (f) Relative pre-tRNA abundance of $\text{tRNA}^{\text{Ile}}_{\text{AAU}}$ across multiple primers covering
1057 distinct genetic loci using RT-qPCR of MDA LM2 vs. MDA-MB-231. Two-sided un-
1058 paired student's t-tests performed, p-values represented *, **, ***, **** as $p < 0.05$,
1059 $p < 0.01$, $p < 0.001$, $p < 0.0001$, respectively.

1060
1061




1062 **Supplementary Figure 2 – $\text{tRNA}^{\text{Ile}}_{\text{UAU}}$ and $\text{tRNA}^{\text{Ile}}_{\text{GAU}}$ levels can be**
1063 **manipulated exogenously.**

1064 (a,b) Northern blot quantification of $\text{tRNA}^{\text{Ile}}_{\text{UAU}}$ relative to U6 of MDA (a) or
1065 HCC1806 (b) Parental cells with control or overexpression of $\text{tRNA}^{\text{Ile}}_{\text{UAU}}$.

1066 (c) Northern blot quantification of $\text{tRNA}^{\text{Ile}}_{\text{UAU}}$ relative to U6 of LM2 cells depleted of
1067 $\text{tRNA}^{\text{Ile}}_{\text{UAU}}$ via CRISPR with Guide 1 or 2 versus control.

1068 (d) $\text{tRNA}^{\text{Ile}}_{\text{GAU}}$ quantification by specific $\text{tRNA}^{\text{Ile}}_{\text{GAU}}$ probe RT-qPCR normalized to
1069 18S probes of LM2 cells with control or overexpression of $\text{tRNA}^{\text{Ile}}_{\text{GAU}}$.

1070 (e,f) $\text{tRNA}^{\text{Ile}}_{\text{GAU}}$ quantification by specific $\text{tRNA}^{\text{Ile}}_{\text{GAU}}$ probe RT-qPCR normalized to
1071 18S probes MDA Parental CRISPRi cells with guides targeting either control or
1072 $\text{tRNA}^{\text{Ile}}_{\text{GAU}}$ (e) or or shRNA targeting control or $\text{tRNA}^{\text{Ile}}_{\text{GAU}}$ (f). Two sided un-paired
1073 student t-tests performed, p-values represented as *, **, *** as $p < 0.05$, $p < 0.01$,
1074 $p < 0.001$.




1075 **Supplementary Figure 3 – Downstream effectors of tRNA^{Ile}_{GAU} depletion and**
 1076 **tRNA^{Ile}_{UAU} overexpression mediate increased growth under metastatic stress**
 1077 **conditions**

1078 (a, b). Histogram of read coverage to demonstrate 3 nucleotide periodicity of the
 1079 coding sequence with respect to the start (a) and stop codon (b) of the reading
 1080 frame.

1081 (c) Volcano plot representing \log_2 fold change vs. $-\log p$ value of translational
 1082 efficiency from ribosomal profiling of MDA tRNA^{Ile}_{GAU} depleted and tRNA^{Ile}_{UAU}
 1083 overexpression cells versus control.

- 1084 (d) Quantification of lung metastatic nodules post extraction after tail vein injection
1085 of 1×10^5 MDA $tRNA^{lle}_{GAU}$ depleted and $tRNA^{lle}_{UAU}$ overexpression cells versus
1086 control.
1087 (e) Relative cell counts of MDA MB 231 control & $tRNA^{lle}_{GAU}$ depletion $tRNA^{lle}_{UAU}$
1088 overexpression cells after 5 days. Two-sided un-paired student's t-tests
1089 performed, p-values represented as *, ** as $p < 0.05$, $p < 0.01$, respectively.
1090 (f) iBAQ values of six candidate downstream effectors, measured by label free
1091 quantification mass spectrometry; 3 biological replicates each.
1092 (g) RT-qPCR quantification of LSM6 cDNA levels normalized to GAPDH on Day 2
1093 of siRNA transfection.
1094 (h) RT-qPCR quantification of PYCARD cDNA levels normalized to GAPDH. Two-
1095 sided un-paired student's t-tests performed, p-values represented **, ***, **** as
1096 $p < 0.01$, $p < 0.001$, $p < 0.0001$, respectively.
1097



1098 **Supplementary Figure 4 – Ribosomal profiling of MDA cells concurrently**
1099 **modulated with $tRNA^{lle}_{GAU}$ depletion & $tRNA^{lle}_{UAU}$ overexpression.**

- 1100 (a) Polysome traces of two representative samples, measured by UV
1101 spectrometry.
1102 (b) Genes with a high abundance of AUA codons were significantly enriched
1103 among genes significantly upregulated in ribosomal protected fragments
1104 (corrected for their transcript changes) in $tRNA^{lle}_{GAU}$ depleted $tRNA^{lle}_{UAU}$
1105 overexpression cells versus control MDA MB 231 cells, measured by ribosomal
1106 profiling. The statistical significance of these enrichments was assessed using
1107 mutual-information calculations and associated Z score (based on randomized
1108 input vectors). Also included is the χ^2 p value for the associated contingency table.
1109 The heatmap was generated using the $-\log$ of the hypergeometric p value for
1110 enrichment and log of p value for depletion (collectively termed the enrichment
1111 score). The red and dark-blue borders indicate the statistical significance of the
1112 calculated hypergeometric p values.
1113 (c) Same as (b) except analyzed for AUC codon enrichment. Codon content scored
1114 for by relative synonymous codon usage score (RSCU).